Sean Laaman
Stock Analyst at Morgan Stanley
(4.05)
# 522
Out of 5,152 analysts
26
Total ratings
66.67%
Success rate
10.23%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics | Initiates: Overweight | $32 | $15.10 | +111.92% | 1 | Mar 2, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $96 → $98 | $65.65 | +49.28% | 2 | Feb 25, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $48 → $49 | $41.14 | +19.11% | 6 | Feb 2, 2026 | |
| AXSM Axsome Therapeutics | Downgrades: Equal-Weight | $196 → $204 | $162.50 | +25.54% | 4 | Jan 8, 2026 | |
| CERT Certara | Maintains: Equal-Weight | $16 → $12 | $7.37 | +62.82% | 2 | Dec 18, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | $10.00 | +100.00% | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $17.80 | +91.01% | 1 | Nov 21, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $90 → $115 | $60.99 | +88.56% | 3 | Oct 30, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $258.75 | +17.49% | 2 | Oct 21, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $350 → $383 | $296.22 | +29.30% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $3 → $1.5 | $2.08 | -27.88% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 | $69.01 | -2.91% | 1 | Feb 14, 2025 |
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $32
Current: $15.10
Upside: +111.92%
BridgeBio Pharma
Feb 25, 2026
Maintains: Overweight
Price Target: $96 → $98
Current: $65.65
Upside: +49.28%
Exelixis
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $48 → $49
Current: $41.14
Upside: +19.11%
Axsome Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $196 → $204
Current: $162.50
Upside: +25.54%
Certara
Dec 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $7.37
Upside: +62.82%
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: $10.00
Upside: +100.00%
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $17.80
Upside: +91.01%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $115
Current: $60.99
Upside: +88.56%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $258.75
Upside: +17.49%
BeOne Medicines AG
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $296.22
Upside: +29.30%
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $2.08
Upside: -27.88%
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $69.01
Upside: -2.91%